Cargando…

Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study

BACKGROUND: Hereditary Inclusion Body Myopathy (HIBM) is an autosomal recessive, adult onset, non-inflammatory neuromuscular disorder with no effective treatment. The causative gene, GNE, codes for UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, which catalyzes the first two reaction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sparks, Susan, Rakocevic, Goran, Joe, Galen, Manoli, Irini, Shrader, Joseph, Harris-Love, Michael, Sonies, Barbara, Ciccone, Carla, Dorward, Heidi, Krasnewich, Donna, Huizing, Marjan, Dalakas, Marinos C, Gahl, William A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1790898/ https://www.ncbi.nlm.nih.gov/pubmed/17261181 http://dx.doi.org/10.1186/1471-2377-7-3

Ejemplares similares

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Identification of an Alu element‐mediated deletion in the promoter region of GNE in siblings with GNE myopathy
por: Garland, Jennifer, et al.
Publicado: (2017)

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications
por: Dalakas, Marinos C.
Publicado: (2020)

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
por: Schmidt, Karsten, et al.
Publicado: (2016)

Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
por: Dalakas, Marinos C.
Publicado: (2023)

Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study
por: Carrillo, Nuria, et al.
Publicado: (2021)

Two novel compound heterozygous mutations in OPA3 in two siblings with OPA3-related 3-methylglutaconic aciduria
por: Lam, Christina, et al.
Publicado: (2014)

Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure (HMERF) in families of diverse ethnic origins
por: Toro, Camilo, et al.
Publicado: (2013)

The Proteomic Profile of Hereditary Inclusion Body Myopathy
por: Sela, Ilan, et al.
Publicado: (2011)

Hereditary Inclusion Body Myopathy (HIBM2)
por: Jay, Chris M., et al.
Publicado: (2009)

Association of the Hermansky-Pudlak syndrome type-3 protein with clathrin
por: Helip-Wooley, Amanda, et al.
Publicado: (2005)

Eosinophils in hereditary and inflammatory myopathies
por: SCHRöDER, THOMAS, et al.
Publicado: (2013)

I-7 Autoimmune Inflammatory Myopathies: Summary on Pathogenesis and Therapies
por: Dalakas, M.
Publicado: (2011)

Hereditary inclusion-body myopathy with sparing of the quadriceps: the many tiles of an incomplete puzzle
por: Broccolini, A., et al.
Publicado: (2011)

Hereditary inclusion body myopathy: A myopathy with unique topography of weakness, yet frequently misdiagnosed: Case series and review of literature
por: Das, Biplab, et al.
Publicado: (2016)

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies
por: Dalakas, Marinos C.
Publicado: (2018)

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
por: Dalakas, Marinos C.
Publicado: (2018)

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost
por: Dalakas, Marinos C.
Publicado: (2017)

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing
por: Dalakas, Marinos C.
Publicado: (2020)

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy
por: Dalakas, Marinos C.
Publicado: (2021)

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2021)

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology
por: Dalakas, Marinos C.
Publicado: (2023)

A novel missense mutation in the GNE gene in an Iranian patient with hereditary inclusion body myopathy
por: Behnam, Mahdiyeh, et al.
Publicado: (2014)

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy
por: Van Wart, Scott, et al.
Publicado: (2021)

Molecular Analysis of the Retinoic Acid Induced 1 Gene (RAI1) in Patients with Suspected Smith-Magenis Syndrome without the 17p11.2 Deletion
por: Vilboux, Thierry, et al.
Publicado: (2011)

Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece
por: Vlachoyiannopoulos, Panayiotis, et al.
Publicado: (2020)

Autoimmune Neurogenic Dysphagia
por: Stathopoulos, Panos, et al.
Publicado: (2021)

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
por: Stathopoulos, Panos, et al.
Publicado: (2022)

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome
por: Yi, Jessica, et al.
Publicado: (2022)

Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
por: Dalakas, Marinos C., et al.
Publicado: (2022)

Assessing Function and Endurance in Adults with Spinal and Bulbar Muscular Atrophy: Validity of the Adult Myopathy Assessment Tool
por: Harris-Love, Michael O., et al.
Publicado: (2014)

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)

Towards Central Nervous System Involvement in Adults with Hereditary Myopathies
por: Reimann, Jens, et al.
Publicado: (2020)

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)
por: Jay, Chris, et al.
Publicado: (2008)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kh25jlfov6813rudhjf961e8ov